Antigen binding protein targeting CD39 and use thereof
By developing high-affinity antibodies or antigen-binding fragments targeting CD39, the problem of CD39 inhibiting immune response in the tumor microenvironment is solved, significantly improving the activity of immune cells and anti-tumor immune response, and effectively inhibiting and immunity of CD39 is achieved. Improvement of treatment.
Patent Information
- Application Number
- PCT/CN2024/096977
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-02
- Filing Date
- 2024-06-03
- Publication Date
- 2024-12-05
AI Technical Summary
Overexpression of CD39 in the tumor microenvironment inhibits the immune response, resulting in weakening of anti-tumor immune response and immunotherapy resistance. It is difficult for the prior art to effectively target and inhibit its function.
Develop an antibody or antigen-binding fragment that targets CD39, which has high affinity (KD value ≤1×10-8M) to bind to CD39, which can effectively inhibit CD39 enzyme activity, improve immune cell function, and reduce regulatory T cells. Immunosuppressive function.
It significantly improves the activity and function of immune cells, reactivates depleted T cells, enhances the anti-tumor immune response, and improves the effect of immunotherapy.
Smart Images

Figure PCTCN2024096977-FTAPPB-I100001 
Figure PCTCN2024096977-FTAPPB-I100002 
Figure PCTCN2024096977-FTAPPB-I100003
Abstract
Description
Antigen binding proteins targeting CD39 and their applications Technical Field
[0001] The present application relates to the field of biomedicine, and specifically to an antibody or antigen-binding fragment thereof targeting CD39, and uses thereof. Background Art
[0002] CD39 (also known as NTPDase1) is a cell membrane enzyme that belongs to the E-NTPDase family (extracellular nucleotide diphosphatase family). It is primarily responsible for the hydrolysis of extracellular ATP and ADP, converting them into AMP, which is then degraded into adenosine by the downstream CD73 molecule. CD39's function is primarily to regulate extracellular nucleotide levels and participate in various physiological and pathological processes.
[0003] In the immune system, CD39 plays a crucial role in regulating and controlling immune responses. CD39 degrades extracellular ATP and ADP, reducing their concentrations during inflammation and immune responses. This process reduces the stimulatory effects of extracellular ATP and ADP on immune cells, thereby alleviating inflammatory responses and immune overactivation. Furthermore, adenosine produced by the ATP-CD39-CD73-adenosine pathway can inhibit the activity of various immune cells by binding to adenosine receptors, further suppressing the immune response.
[0004] CD39 plays an important role in the development and progression of various diseases. Inflammatory diseases (such as rheumatoid arthritis and inflammatory bowel disease) and immune diseases (such as autoimmune diseases and organ transplant rejection) are both associated with abnormal activation of the immune system, and CD39 dysfunction may be a key factor.
[0005] The tumor microenvironment harbors multiple immunosuppressive mechanisms, including an increase in immunosuppressive cells, the production of immunosuppressive factors, and increased expression of immunosuppressive receptors. This suppression of immune cell function weakens the anti-tumor immune response. Therefore, researchers are constantly searching for new tumor immune targets to develop novel immunotherapy strategies.
[0006] Studies have shown that CD39 expression levels are often significantly increased in tumor tissues, closely associated with tumor progression and poor prognosis. CD39 plays a crucial role in tumor immune evasion and drug resistance. The hypoxic tumor microenvironment often triggers massive cell death, releasing large amounts of ATP. CD39, which is widely upregulated in the tumor microenvironment, degrades extracellular ATP and ADP to produce adenosine, thereby reducing the pro-inflammatory effects of ATP and ADP while increasing adenosine concentrations to further suppress the activity and function of immune cells. Within the tumor microenvironment, CD39 is often significantly upregulated in a variety of cells, which is also associated with tumor immune evasion and resistance to immunotherapy. Therefore, as an enzyme that plays a crucial role in immune regulation, CD39 is a potential therapeutic target. The development of corresponding antibodies or inhibitors has broad application value.
[0007] Summary of the Invention
[0008] The present application provides an antibody or antigen-binding fragment thereof that can specifically bind to CD39 protein, which has one or more of the following properties: (1) can be used to bind to 1×10 -8 M or lower KD value binds to CD39; (2) can bind to human CD39, mouse CD39, or cynomolgus monkey CD39; (3) can effectively inhibit CD39 protease activity; (4) can improve the function of immune cells, for example, promote the proliferation of immune cells; (5) can reduce the immunosuppressive function of regulatory T cells and reactivate exhausted T cells.
[0009] On the one hand, the present application provides an antibody or an antigen-binding fragment thereof, which can specifically bind to the CD39 protein, wherein the antibody or the antigen-binding fragment thereof comprises at least one CDR in the antibody heavy chain variable region (VH), and the VH comprises the amino acid sequence shown in any one of SEQ ID NO: 8, SEQ ID NO: 16, SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 32, SEQ ID NO: 37 and SEQ ID NO: 41.
[0010] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a HCDR3 comprising the amino acid sequence shown in any one of SEQ ID NO: 3, SEQ ID NO: 54, and SEQ ID NO: 55.
[0011] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a HCDR3 comprising the amino acid sequence of any one of SEQ ID NO:3, SEQ ID NO:11, SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:29, and SEQ ID NO:33.
[0012] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a HCDR2 comprising the amino acid sequence of any one of SEQ ID NO: 2, SEQ ID NO: 10, SEQ ID NO: 23, and SEQ ID NO: 28.
[0013] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a HCDR1 comprising the amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 53, and SEQ ID NO: 22.
[0014] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a HCDR1 comprising the amino acid sequence of any one of SEQ ID NO: 1, SEQ ID NO: 9, SEQ ID NO: 17, and SEQ ID NO: 22.
[0015] In certain embodiments, the antibody or antigen-binding fragment thereof comprises HCDR1, HCDR2, and HCDR3, wherein the HCDR1, HCDR2, and HCDR3 comprise an amino acid sequence selected from the group consisting of:
[0016] (1) the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 1, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 2, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 3;
[0017] (2) the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 9, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 10, and the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 11;
[0018] (3) the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 17, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 10, and the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 18;
[0019] (4) the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 22, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 23, and the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 24;
[0020] (5) the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 22, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 28, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 29; or
[0021] (6) The HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 22, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 28, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 33.
[0022] In certain embodiments, the antibody or antigen-binding fragment thereof comprises H-FR1, the C-terminus of the H-FR1 is directly or indirectly connected to the N-terminus of the HCDR1, and the H-FR1 comprises the amino acid sequence shown in SEQ ID NO:56.
[0023] In certain embodiments, the H-FR1 of the antibody or antigen-binding fragment thereof comprises the amino acid sequence shown in any one of SEQ ID NO:4, SEQ ID NO:12, SEQ ID NO:19, SEQ ID NO:34 and SEQ ID NO:38.
[0024] In certain embodiments, the antibody or antigen-binding fragment thereof comprises H-FR2, wherein the H-FR2 is located between the HCDR1 and HCDR2, and the H-FR2 comprises the amino acid sequence shown in SEQ ID NO:57.
[0025] In certain embodiments, the H-FR2 of the antibody or antigen-binding fragment thereof comprises the amino acid sequence shown in any one of SEQ ID NO:5, SEQ ID NO:13, SEQ ID NO:20, SEQ ID NO:25, SEQ ID NO:30 and SEQ ID NO:35.
[0026] In certain embodiments, the antibody or antigen-binding fragment thereof comprises H-FR3, wherein the H-FR3 is located between the HCDR2 and the HCDR3, and the H-FR3 comprises the amino acid sequence shown in SEQ ID NO:58.
[0027] In certain embodiments, the H-FR3 of the antibody or antigen-binding fragment thereof comprises the amino acid sequence shown in any one of SEQ ID NO:6, SEQ ID NO:14, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:36 and SEQ ID NO:40.
[0028] In certain embodiments, the antibody or antigen-binding fragment thereof comprises H-FR4, the N-terminus of the H-FR4 is connected to the C-terminus of the HCDR3, and the H-FR4 comprises the amino acid sequence shown in SEQ ID NO:59.
[0029] In certain embodiments, the H-FR4 of the antibody or antigen-binding fragment thereof comprises the amino acid sequence shown in any one of SEQ ID NO:7, SEQ ID NO:15 and SEQ ID NO:39.
[0030] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence shown in any one of SEQ ID NO:8, SEQ ID NO:16, SEQ ID NO:21, SEQ ID NO:27, SEQ ID NO:32, SEQ ID NO:37 and SEQ ID NO:41.
[0031] In certain embodiments, the antigen-binding fragment is a VHH.
[0032] In certain embodiments, the VHH comprises the amino acid sequence shown in any one of SEQ ID NO:8, SEQ ID NO:16, SEQ ID NO:21, SEQ ID NO:27, SEQ ID NO:32, SEQ ID NO:37 and SEQ ID NO:41.
[0033] In certain embodiments, the antibody or antigen-binding fragment thereof comprises an antibody heavy chain constant region.
[0034] In certain embodiments, the antibody heavy chain constant region is derived from a human IgG constant region.
[0035] In certain embodiments, the antibody heavy chain constant region is derived from a human IgG4 constant region.
[0036] In certain embodiments, the antibody heavy chain constant region comprises the amino acid sequence shown in SEQ ID NO:44.
[0037] In certain embodiments, the antigen-binding fragment comprises a Fab, a Fab', an Fv fragment, a F(ab')2, a F(ab)2, a scFv, a di-scFv and / or a dAb.
[0038] In certain embodiments, the antibody is selected from one or more of the following groups: a monoclonal antibody, a chimeric antibody, a humanized antibody, and a fully human antibody.
[0039] In certain embodiments, the CD39 protein is human CD39 protein, mouse CD39 protein or cynomolgus monkey CD39 protein.
[0040] On the other hand, the present application also provides a bispecific antibody or an antigen-binding fragment thereof, which comprises a first binding domain that specifically binds to the CD39 protein, and the first binding domain comprises the antibody or the antigen-binding fragment thereof.
[0041] In certain embodiments, the first binding domain that specifically binds to the CD39 protein is a VHH that specifically binds to CD39.
[0042] In certain embodiments, the bispecific antibody or antigen-binding fragment thereof comprises a second binding domain that specifically binds to the PD-L1 protein.
[0043] In certain embodiments, the second binding domain that specifically binds to the PD-L1 protein comprises a PD-L1 antibody or an antigen-binding fragment thereof.
[0044] In certain embodiments, the PD-L1 antibody or antigen-binding fragment thereof comprises HCDR1, HCDR2, and HCDR3, wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:45, the HCDR2 comprises the amino acid sequence of SEQ ID NO:46, and the HCDR3 comprises the amino acid sequence of SEQ ID NO:47.
[0045] In certain embodiments, the PD-L1 antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence shown in SEQ ID NO: 48.
[0046] In certain embodiments, the PD-L1 antibody or antigen-binding fragment thereof comprises LCDR1, LCDR2, and LCDR3, wherein the LCDR1 comprises the amino acid sequence of SEQ ID NO:49, the LCDR2 comprises the amino acid sequence of SEQ ID NO:50 (GNS), and the LCDR3 comprises the amino acid sequence of SEQ ID NO:51.
[0047] In certain embodiments, the PD-L1 antibody or antigen-binding fragment thereof comprises a VL comprising the amino acid sequence shown in SEQ ID NO:52.
[0048] In certain embodiments, the PD-L1 antibody or antigen-binding fragment thereof comprises an antibody heavy chain constant region.
[0049] In certain embodiments, the PD-L1 antibody or antigen-binding fragment thereof comprises an antibody light chain constant region.
[0050] In certain embodiments, the antibody heavy chain constant region is derived from a human IgG constant region.
[0051] In certain embodiments, the C segment of the VHH that specifically binds to CD39 in the bispecific antibody or antigen-binding fragment thereof is directly or indirectly linked to the N-terminus of the PD-L1 antibody or antigen-binding fragment thereof.
[0052] In certain embodiments, the N-segment of the VHH that specifically binds to CD39 in the bispecific antibody or antigen-binding fragment thereof is directly or indirectly linked to the C-terminus of the PD-L1 antibody or antigen-binding fragment thereof.
[0053] In certain embodiments, the indirect linkage comprises linkage via a linker.
[0054] In certain embodiments, the linker comprises an amino acid sequence represented by (G4S)n, wherein n is a positive integer of 1-10.
[0055] In certain embodiments, the bispecific antibody or antigen-binding fragment thereof comprises a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain comprises the heavy chain variable region of the PD-L1 antibody or antigen-binding fragment thereof, the heavy chain constant region of the PD-L1 antibody or antigen-binding fragment thereof, and the VHH that specifically binds to CD39, and the second polypeptide chain comprises the light chain variable region and light chain constant region of the PD-L1 antibody or antigen-binding fragment thereof.
[0056] In certain embodiments, the bispecific antibody or antigen-binding fragment thereof comprises a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain comprises the heavy chain variable region of the PD-L1 antibody or antigen-binding fragment thereof, the heavy chain constant region of the PD-L1 antibody or antigen-binding fragment thereof, a linker, and the VHH that specifically binds to CD39, and the second polypeptide chain comprises the light chain variable region and light chain constant region of the PD-L1 antibody or antigen-binding fragment thereof.
[0057] In certain embodiments, the bispecific antibody or antigen-binding fragment thereof comprises a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain comprises, from N-terminus to C-terminus, the heavy chain variable region of the PD-L1 antibody or antigen-binding fragment thereof, the heavy chain constant region of the PD-L1 antibody or antigen-binding fragment thereof, a linker, and the VHH that specifically binds to CD39, and the second polypeptide chain comprises the light chain variable region and light chain constant region of the PD-L1 antibody or antigen-binding fragment thereof.
[0058] In certain embodiments, the bispecific antibody or antigen-binding fragment thereof comprises a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain comprises, from N-terminus to C-terminus, the VHH that specifically binds to CD39, a linker, the heavy chain variable region of the PD-L1 antibody or antigen-binding fragment thereof, and the heavy chain constant region of the PD-L1 antibody or antigen-binding fragment thereof, and the second polypeptide chain comprises the light chain variable region and light chain constant region of the PD-L1 antibody or antigen-binding fragment thereof.
[0059] On the other hand, the present application also provides a polypeptide comprising the antibody or antigen-binding fragment thereof, or the bispecific antibody or antigen-binding fragment thereof.
[0060] In another aspect, the present application also provides one or more isolated nucleic acid molecules encoding the antibody or antigen-binding fragment thereof, or the bispecific antibody or antigen-binding fragment thereof.
[0061] In certain embodiments, the nucleic acid molecule further comprises a nucleic acid molecule encoding another protein.
[0062] In certain embodiments, the additional protein comprises a chimeric antigen receptor (CAR).
[0063] On the other hand, the present application also provides a vector comprising the nucleic acid molecule.
[0064] In certain embodiments, the nucleic acid molecule encoding the other protein and the nucleic acid molecule encoding the antibody or antigen-binding fragment thereof are located in the same vector.
[0065] In certain embodiments, the nucleic acid molecule encoding the other protein and the nucleic acid molecule encoding the antibody or antigen-binding fragment thereof are located in different vectors.
[0066] On the other hand, the present application also provides a cell comprising the nucleic acid molecule or the vector.
[0067] In certain embodiments, the cells comprise immune cells.
[0068] In certain embodiments, the immune cells include T cells, NK cells, and / or macrophages.
[0069] In certain embodiments, the cells further comprise and / or express other proteins.
[0070] In certain embodiments, the additional protein further comprises a chimeric antigen receptor (CAR).
[0071] On the other hand, the present application also provides a pharmaceutical combination comprising the following components:
[0072] (1) the antibody or antigen-binding fragment thereof, or the bispecific antibody or antigen-binding fragment thereof;
[0073] (2) Cells.
[0074] In certain embodiments, the cell comprises a modified cell or an unmodified cell.
[0075] In certain embodiments, the modified cells comprise and / or express a CAR.
[0076] In certain embodiments, the cells comprise immune cells.
[0077] In certain embodiments, the cells include T cells, NK cells, and / or macrophages.
[0078] On the other hand, the present application also provides a method for preparing the antibody or its antigen-binding fragment or bispecific antibody or its antigen-binding fragment, comprising culturing the cell under conditions where the antibody or its antigen-binding fragment or bispecific antibody or its antigen-binding fragment is expressed.
[0079] On the other hand, the present application also provides the use of the antibody or antigen-binding fragment thereof, the bispecific antibody or antigen-binding fragment thereof, the nucleic acid molecule, the cell, the drug combination, or the pharmaceutical composition in the preparation of a drug for preventing and / or treating a disease and / or condition.
[0080] On the other hand, the present application also provides a method for preventing and / or treating a disease and / or condition, comprising administering the antibody or antigen-binding fragment thereof, the bispecific antibody or antigen-binding fragment thereof, the nucleic acid molecule, the cell, the drug combination, or the pharmaceutical composition to a subject in need.
[0081] On the other hand, the present application also provides the antibody or antigen-binding fragment thereof, the bispecific antibody or antigen-binding fragment thereof, the nucleic acid molecule, the cell, the drug combination, or the pharmaceutical composition, which is used to prevent and / or treat diseases and / or conditions.
[0082] In certain embodiments, the disease and / or condition comprises a tumor.
[0083] In certain embodiments, the tumor comprises a solid tumor and / or a hematological tumor.
[0084] In certain embodiments, the tumor comprises a tumor affected by CD39 activity.
[0085] Those skilled in the art can easily discern other aspects and advantages of the present application from the detailed description below. In the detailed description below, only exemplary embodiments of the present application are shown and described. As will be appreciated by those skilled in the art, the content of this application enables those skilled in the art to modify the disclosed specific embodiments without departing from the spirit and scope of the invention to which this application relates. Accordingly, the descriptions in the drawings and specification of this application are merely exemplary and not restrictive. BRIEF DESCRIPTION OF THE DRAWINGS
[0086] The specific features of the inventions of this application are set forth in the appended claims. The features and advantages of the inventions of this application can be better understood by referring to the exemplary embodiments described in detail below and the accompanying drawings. A brief description of the drawings is as follows:
[0087] FIG1 shows the affinity of the antibodies or antigen-binding fragments thereof described in the present application to human CD39 protein.
[0088] Figures 2A-2B show the binding of the antibodies or antigen-binding fragments thereof described in the present application to human CD39 on the cell surface.
[0089] Figures 3A-3C show the binding of the antibodies or antigen-binding fragments described in the present application to human, mouse, and cynomolgus monkey CD39 proteins.
[0090] Figures 4A-4B show the enzyme activity inhibition function detection of the antibodies or antigen-binding fragments thereof described in the present application at the protein level.
[0091] Figures 5A-5B show the enzyme activity inhibition function detection of the antibodies or antigen-binding fragments thereof described in the present application at the cellular level.
[0092] FIG6 shows the proliferation-promoting effect of the antibodies or antigen-binding fragments thereof described in the present application on PBMC-derived T cells.
[0093] FIG7 shows a schematic diagram of the CAR structural design of CAR-T cells that secrete the antibodies or antigen-binding fragments thereof described in this application.
[0094] FIG8 shows the expression detection of inhibitory markers on the surface of CAR-T cells that secrete the antibodies or antigen-binding fragments thereof described in this application after stimulation with tumor cells.
[0095] FIG9 shows the affinity of the humanized antibody or antigen-binding fragment thereof described in the present application to human CD39 protein.
[0096] FIG10 shows the enzyme activity inhibition function test of the humanized antibody or antigen-binding fragment thereof described in the present application at the protein level.
[0097] FIG11 shows the enzyme activity inhibition function test of the humanized antibody or antigen-binding fragment thereof described in the present application at the cellular level.
[0098] FIG12 shows the effect of the humanized antibody or antigen-binding fragment thereof described in the present application on improving the proliferation of CAR-T cells.
[0099] FIG13 shows a structural design diagram of the bispecific antibody described in the present application.
[0100] FIG14 shows the purity test of the bispecific antibody described in the present application.
[0101] Figures 15A-15C show the tumor-suppressing effect of the bispecific antibodies described in this application.
[0102] Figure 16 shows the schematic structural diagram of MSLN-CART that does not secrete antibodies or auto-secretes antibodies B391-hF04, YN035 (scFv), and B391-hF04+YN035 (scFv).
[0103] FIG17A shows the statistical changes in tumor growth after administration of different groups of CAR-T cells.
[0104] Figure 17B shows the changes in tumor volume after administration of different groups of CAR-T cells.
[0105] FIG17C shows the changes in body weight of mice administered with different groups of CAR-T cells. DETAILED DESCRIPTION
[0106] The following describes the implementation of the present invention through specific embodiments. People familiar with this technology can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.
[0107] Definition of terms
[0108] In this application, the term "antibody" generally refers to a polypeptide molecule that can specifically recognize and / or neutralize a specific antigen. For example, an antibody may comprise an immunoglobulin composed of a heavy (H) chain and / or a light (L) chain, and includes any molecule comprising its antigen-binding portion. The term "antibody" includes monoclonal antibodies, antibody fragments or antibody derivatives, including but not limited to human antibodies, humanized antibodies, chimeric antibodies, single-chain antibodies (e.g., scFv), single-domain antibodies (nanoantibodies), and antibody fragments that bind to antigens (e.g., Fab, Fab', (Fab)2 and VHH fragments). The term "antibody" also includes all recombinant forms of antibodies, such as antibodies expressed in prokaryotic cells, non-glycosylated antibodies, and any antibody fragments and derivatives thereof that bind to antigens described herein. Each chain can be composed of a variable region and a constant region. The variable region can be further divided into hypervariable regions called complementary determining regions (CDRs), which are interspersed in more conserved regions called framework regions (FRs). Each VH and / or VL can be composed of three CDRs and four FR regions, which can be arranged in the following order from amino terminus to carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The variable region of the heavy chain and / or light chain contains a binding domain that interacts with the antigen. The constant region of the antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.
[0109] In the present application, the term "antigen-binding fragment" refers to a portion of an intact antibody and refers to the antigen-determining variable region of an intact antibody. For example, the antigen-binding fragment may include Fab, Fab', F(ab')2, Fv segments and single-chain Fv fragments, tandem Fv fragments, VHH, and bispecific antibodies. For example, the antigen-binding fragment may be a VHH. For example, the antigen-binding fragment may bind to CD39. For example, the antigen-binding fragment may be specific for CD39. In the present application, the term "VHH" generally refers to an antibody that comprises the variable antigen-binding domain of a heavy chain antibody. VHH may also be referred to as a nanobody (Nb) and / or a single-domain antibody.
[0110] In this application, the term "K D " is used interchangeably with "KD" and generally refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, expressed in M (mol / L). KD can be calculated using the concentrations of substance AB and the dissociated substances A and B: KD = c(A) * c(B) / c(AB). As can be seen from this formula, a larger KD value indicates greater dissociation, meaning a weaker affinity between substances A and B; conversely, a smaller KD value indicates less dissociation, meaning a stronger affinity between substances A and B.
[0111] In this application, the term "monoclonal antibody" generally refers to an antibody comprising a group of substantially homologous antibodies, i.e., each antibody comprising the group is identical except for possible naturally occurring mutations present in trace amounts. Monoclonal antibodies are highly specific and are directed against a single antigenic site. In addition, in contrast to polyclonal antibody preparations comprising different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. The modifier "monoclonal" is not to be interpreted as requiring the production of antibodies by any particular method. For example, the monoclonal antibody can be prepared by hybridoma technology or by using recombinant DNA methods to produce monoclonal antibodies in bacteria, eukaryotic animals, or plant cells. Monoclonal antibodies can also be obtained from phage antibody libraries, using, for example, the techniques described in Clackson et al., Nature, 352: 624-628 (1991) and Marks et al., Mol. Biol., 222: 581-597 (1991).
[0112] In this application, the term "single-chain antibody" generally refers to (scFv) a molecule composed of the variable regions of the heavy and light chains of an antibody connected by a short peptide linker.
[0113] In this application, the term "chimeric antibody" generally refers to an antibody in which a portion of each heavy chain or light chain amino acid sequence is homologous to the corresponding amino acid sequence in an antibody from a specific species, or belongs to a specific category, while the remaining segments of the chain are homologous to the corresponding sequences in another species. For example, the variable regions of the light chain or heavy chain are all from the variable regions of an antibody from one animal species (such as mouse, rat, etc.), while the constant portion is homologous to the antibody sequence from another species (such as human). For example, to obtain a chimeric antibody, non-human B cells or hybridoma cells can be used to produce the variable region, while the constant region combined with it is from human. The variable region has the advantage of being easy to prepare, and its specificity is not affected by the source of the constant region combined with it. At the same time, since the constant region of the chimeric antibody can be derived from humans, the possibility of the chimeric antibody triggering an immune response when injected will be lower than that of an antibody using a non-human constant region.
[0114] In this application, the term "humanized antibody" generally refers to a modified antibody that uses genetic engineering techniques to reduce the immunogenicity of antibodies, immunoglobulin binding proteins and polypeptides derived from non-human species (such as mice or rats) to humans while still retaining the antigen-binding properties of the original antibody. For example, CDR grafting (Jones et al., Nature 321:522 (1986)) and variants thereof can be used; including "reshaping", (Verhoeyen, et al., 1988 Science 239:1534-1536; Riechmann, et al., 1988 Nature 332:323-337; Tempest, et al., Bio / Technol 1991 9:266-271), "hyperchimerization", (Queen, et al., 1989 Proc Natl Acad Sci USA 86:10029-10033; Co, et al., 1991 Proc Natl Acad Sci USA 88:2869-2873; Co, et al., 1992 J Immunol The binding domain of non-human origin is humanized by techniques such as cloning (Mark, et al., "Derivation of therapeutically active humanized and veneered anti-CD18 antibodies." In: Metcalf BW, Dalton BJ, eds. Cellular adhesion: molecular definition to therapeutic potential. New York: Plenum Press, 1994: 291-312). If other regions, such as hinge regions and constant region domains, are also derived from non-human sources, these regions can also be humanized.
[0115] In this application, the term "fully human antibody" generally refers to an antibody whose entirety (including the constant region, CH and / or CL regions) is encoded by genes of human origin. Fully human antibodies can greatly reduce the immune side effects caused by heterologous antibodies to the human body.
[0116] In this application, the term "bispecific antibody (BsAbs)" generally refers to an antibody or antibody construct with dual specificity in its binding arm. Naturally occurring antibodies are monospecific and have the same specificity in their antigen-binding arms. Bispecific antibodies are obtained from two different sources and constructed by recombinant DNA or cell fusion technology so that they retain the two specificities of the original antibody. Bispecific antibodies carry two different antigen-binding sites. The Fc portion of a bispecific antibody is different from the Fc portion in any parent monospecific antibody. Since bispecific antibodies have dual specificity for both drugs and tumor cells, in theory, they can lead to higher drug accumulation in tumors than in tumor-free sites in the body. Most bispecific new antibodies can redirect cytotoxic effector cells (such as Tc cells, NK cells, neutrophils) to target cells (such as tumor cells). Bispecific antibodies can simultaneously block two different mediators / pathways that play unique or overlapping functions in pathogenesis, and may also increase binding specificity by interacting with two different cell surface antigens instead of one. (Fanger, Michael W., and Paul M. Guyre. "Bispecific antibodies for targeted cellular cytotoxicity." Trends in biotechnology, 1991: 375-380), (Fan, Gaowei, et al. "Bispecific antibodies and their applications." Journal of hematology&oncology, 2015: 130).
[0117] In this application, the term "IgG" refers to polypeptides belonging to the class of antibodies substantially encoded by the recognized immunoglobulin gamma genes. In humans, this class includes IgG1, IgG2, IgG3, and IgG4. In mice, this class includes IgG1, IgG2a, IgG2b, and IgG3.
[0118] In the present application, the term "chimeric antigen receptor" (CAR) generally refers to a recombinant polypeptide comprising at least an extracellular domain, a transmembrane region, and an intracellular domain that specifically binds to an antigen or target. For example, a hinge region is included between the extracellular domain and the transmembrane region. For example, the chimeric antigen receptor may also include a low-density lipoprotein receptor-related protein or a fragment thereof. For example, the chimeric antigen receptor may include a signal peptide. The extracellular domain of CAR binds to the target antigen on the surface of the target cell, resulting in CAR clustering and transmitting the activation stimulus to the CAR-containing cell. CAR redirects the specificity of immune effector cells and triggers proliferation, cytokine production, phagocytosis and / or production of molecules that can mediate cell death of cells expressing the target antigen in a manner independent of major histocompatibility (MHC).
[0119] In this application, the terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The term may be used to refer to an amino acid polymer in which one or more amino acid residues is a synthetic chemical mimetic of the corresponding naturally occurring amino acid, as well as to natural amino acid polymers, those containing modified residues, and non-natural amino acid polymers. For example, the polypeptide may include the antigen-binding protein described herein.
[0120] In this application, the term "nucleic acid molecule" generally refers to isolated forms of nucleotides, deoxyribonucleotides or ribonucleotides of any length, or their analogs, isolated from their natural environment or artificially synthesized.
[0121] In this application, the term "vector" generally refers to a nucleic acid molecule that can self-replicate in a suitable host, which transfers the inserted nucleic acid molecule into and / or between host cells. The vector may include a vector primarily used for inserting DNA or RNA into a cell, a vector primarily used for replicating DNA or RNA, and a vector primarily used for expression of the transcription and / or translation of DNA or RNA. The vector also includes a vector with a variety of the above-mentioned functions. The vector may be a polynucleotide that can be transcribed and translated into a polypeptide when introduced into a suitable host cell. Typically, the vector can produce a desired expression product by cultivating a suitable host cell containing the vector.
[0122] In the present application, the term "cell" refers to cells that may be modified or unmodified. For example, unmodified cells may be cells of natural origin, modified cells may be cells to which nucleic acids are transfected, and the term "cell" includes prokaryotic cells used for plasmid propagation, and eukaryotic cells used for nucleic acid expression and encoded polypeptide production. For example, cells may include the antigen-binding protein, the nucleic acid molecule and / or the vector. For another example, the cell may be a modified or unmodified immune effector cell. The term "immune effector cell" generally refers to an immune cell that participates in an immune response and exercises effector functions. For example, the exercise of effector functions may include clearing foreign antigens or promoting immune effector responses, etc. For example, immune effector cells may include T cells, B cells, natural killer cells (NK cells), macrophages, NKT cells, monocytes, dendritic cells, granulocytes, lymphocytes, leukocytes, peripheral blood mononuclear cells, embryonic stem cells, lymphocyte progenitor cells and / or pluripotent stem cells. For example, immune effector cells may be T cells.
[0123] In this application, the term "specific binding" or "specific" generally refers to a measurable and reproducible interaction, such as binding between a target and an antibody, that can determine the presence of a target in the presence of a heterogeneous population of molecules (including biomolecules). For example, an antibody that specifically binds to a target (which may be an epitope) may be one that binds to that target with greater affinity, avidity, more readily, and / or for a longer duration than it binds to other targets. In certain embodiments, an antibody specifically binds to an epitope on a protein that is conserved among proteins of different species. In certain embodiments, specific binding may include, but does not require, exclusive binding.
[0124] In this application, the term "subject" generally refers to a human or non-human animal, including but not limited to a cat, dog, horse, pig, cow, sheep, rabbit, mouse, rat, or monkey.
[0125] In the present application, the proteins, polypeptides and / or amino acid sequences involved should also be understood to include at least the following scope: variants or homologs that have the same or similar functions as the proteins or polypeptides.
[0126] In the present application, the variant may be, for example, a protein or polypeptide in which one or more amino acids have been substituted, deleted or added in the amino acid sequence of the protein and / or the polypeptide (e.g., specifically binding to CD39). For example, the functional variant may comprise a protein or polypeptide having an amino acid change by at least 1, for example, 1-30, 1-20 or 1-10, for example, 1, 2, 3, 4 or 5 amino acid substitutions, deletions and / or insertions. The functional variant may substantially retain the biological properties of the protein or polypeptide before the change (e.g., substitution, deletion or addition). For example, the functional variant may retain at least 60%, 70%, 80%, 90%, or 100% of the biological activity (e.g., antigen binding ability) of the protein or polypeptide before the change. For example, the substitution may be a conservative substitution.
[0127] In the present application, the homolog can be a protein or polypeptide having at least about 85% (e.g., at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more) sequence homology with the amino acid sequence of the protein and / or the polypeptide (e.g., specifically binding to CD39).
[0128] In the present application, described homology generally refers to the similarity, similarity or association between two or more sequences.Can calculate " sequence homology per-cent " in the following manner: two sequences to be compared are compared in comparison window, determine that there is identical nucleic acid base (for example, A, T, C, G, I) or identical amino acid residue (for example, Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) number in the position to obtain the number of matching positions, with the number of matching positions divided by the total number of positions (that is, window size) in the comparison window, and result is multiplied by 100, to produce sequence homology per-cent.Comparison carried out in order to determine the sequence homology per-cent, can realize by several ways known in the art, for example, use publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximum alignment over the full length of the sequences being compared or within a region of interest. Homology can also be determined using the following methods: FASTA and BLAST. A description of the FASTA algorithm can be found in W. R. Earson and D. J. Lipman, "Improved tools for biological sequence comparison," Proc. Natl. Acad. Sci., 85: 2444-2448, 1988; and D. J. Lipman and W. R. Earson, "Rapid and sensitive protein similarity search," Science, 227: 1435-1441, 1989. A description of the BLAST algorithm can be found in S. Altschul, W. Gish, W. Miller, E. W. Myers, and D. Lipman, "A basic local alignment search tool," J. Mol. Biol., 215: 403-410, 1990.
[0129] In this application, the term "comprising" generally means including, encompassing, containing or encompassing. In some cases, it also means "being", "consisting of...".
[0130] In this application, the term "about" generally refers to a variation within a range of 0.5%-10% above or below the specified value, for example, a variation within a range of 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below the specified value.
[0131] Detailed Description of the Invention
[0132] Antibodies or antigen-binding fragments thereof
[0133] In one aspect, the present application provides an antibody or antigen-binding fragment thereof, which is 1×10 -8 M or less (for example, the K D The value is no higher than about 5×10 -9 M, not higher than about 3×10 -9 M, not higher than about 1×10 -9 M, not higher than about 9×10 -10 M, not higher than about 8×10 -10 M, not higher than about 7×10 -10 M, not higher than about 6×10 -10 M, not higher than about 5×10 -10 M, not higher than about 4×10 -10 M, not higher than about 3×10 -10 M, not higher than about 2×10 -10 M, not higher than 1×10 -10 M, not higher than about 9×10 -11 M, not higher than about 8×10 -11 M, not higher than about 7×10 -11 M, not higher than about 6×10 -11 M, not higher than about 1×10 -11 M or less) D The values were combined with CD39 protein.
[0134] The antibodies or antigen-binding fragments thereof described in the present application can specifically bind to the CD39 protein.
[0135] In certain embodiments, the CD39-targeting antibody or antigen-binding fragment thereof described herein can block the ATPase activity of CD39, reduce the production of adenosine, maintain the ATP level in the tumor microenvironment, and promote the activation of T cells by dendritic cells.
[0136] In certain embodiments, the CD39-targeting antibodies or antigen-binding fragments thereof described herein can reduce the immunosuppressive function of regulatory T cells and reactivate exhausted T cells.
[0137] In the present application, the antigen-binding protein may include an antibody or an antigen-binding fragment thereof. In the present application, the antigen-binding fragment may include Fab, Fab', F(ab)2, Fv fragment, F(ab')2, scFv, di-scFv, VHH and / or dAb. In the present application, the antibody may include a monoclonal antibody, a chimeric antibody, a humanized antibody and a fully human antibody.
[0138] In the present application, the antibody may be a single domain antibody. In the present application, the antigen binding fragment may be a VHH.
[0139] In the present application, when the amino acid sequence of the antibody or its antigen-binding fragment is defined, a variant of the antibody or its antigen-binding fragment is included. In the present application, the variant can be an amino acid sequence having substantially the same function (e.g., capable of specific binding to CD39) and having at least 85% or more (e.g., at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or higher) sequence identity thereto. In certain embodiments, the variant of the amino acid sequence is an amino acid sequence having substantially the same function (e.g., capable of specific binding to PD-L1) and comprising one or more (e.g., 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10 or more) amino acids added, deleted or replaced therewith. For another example, the variants described in the present application can be selected from the following groups: proteins or polypeptides in which one or more amino acids are substituted, deleted or added in the antibody or the antigen-binding fragment thereof; and proteins or polypeptides having a sequence homology of more than 85% (e.g., at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more) with the antibody or the antigen-binding fragment thereof.
[0140] In the present application, the antibody or antigen-binding fragment thereof may comprise at least one CDR in the antibody heavy chain variable region (VH), and the VH comprises the amino acid sequence shown in any one of SEQ ID NO:8, SEQ ID NO:16, SEQ ID NO:21, SEQ ID NO:27, SEQ ID NO:32, SEQ ID NO:37 and SEQ ID NO:41.
[0141] The CDR of an antibody, also known as the complementarity determining region, is part of the variable region. The amino acid residues in this region can contact the antigen or antigenic epitope. Antibody CDRs can be determined using a variety of coding systems, such as CCG, Kabat, Chothia, IMGT, AbM, and a combination of Kabat / Chothia. These coding systems are known in the art, and for details, see, for example, http: / / www.bioinf.org.uk / abs / index.html#kabatnum. Those skilled in the art can use different coding systems to determine the CDR region based on the sequence and structure of the antibody. Using different coding systems, there may be differences in the CDR region. In this application, the CDR covers CDR sequences obtained by any CDR division method; it also covers variants thereof, wherein the variant includes the amino acid sequence of the CDR being substituted, deleted, and / or having one or more amino acids added. For example, 1-30, 1-20 or 1-10, and for example 1, 2, 3, 4, 5, 6, 7, 8 or 9 amino acid substitutions, deletions and / or insertions; homologs thereof are also encompassed, and the homologs can be amino acid sequences having at least about 85% (e.g., at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more) sequence homology to the amino acid sequence of the CDR. In the present application, the isolated antigen-binding protein is defined by the IMGT coding system.
[0142] In the present application, the antibody or antigen-binding fragment thereof may comprise a HCDR3, and the HCDR3 may comprise the amino acid sequence shown in any one of SEQ ID NO: 3, SEQ ID NO: 54, and SEQ ID NO: 55. For example, the HCDR3 may comprise the amino acid sequence shown in any one of SEQ ID NO: 3, SEQ ID NO: 11, SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO: 29, and SEQ ID NO: 33.
[0143] In the present application, the antibody or antigen-binding fragment thereof may comprise HCDR2, and the HCDR2 may comprise the amino acid sequence shown in any one of SEQ ID NO: 2, SEQ ID NO: 10, SEQ ID NO: 23 and SEQ ID NO: 28.
[0144] In the present application, the antibody or antigen-binding fragment thereof may comprise a HCDR1, and the HCDR1 may comprise the amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 53, and SEQ ID NO: 22. For example, the HCDR1 may comprise the amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 9, SEQ ID NO: 17, and SEQ ID NO: 22.
[0145] In the present application, the antibody or antigen-binding fragment thereof may comprise HCDR1, HCDR2 and HCDR3.
[0146] For example, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 1, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 2, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 3.
[0147] For example, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:9, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:10, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:11.
[0148] For example, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 17, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 10, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 18.
[0149] For example, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 22, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 23, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 24.
[0150] For example, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 22, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 28, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 29.
[0151] For example, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 22, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 28, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 33.
[0152] In the present application, the antibody or antigen-binding fragment thereof may comprise H-FR1, H-FR2, H-FR3 and H-FR4.
[0153] For example, the H-FR1 may comprise the amino acid sequence shown in SEQ ID NO: 56, the H-FR2 may comprise the amino acid sequence shown in SEQ ID NO: 57, the H-FR3 may comprise the amino acid sequence shown in SEQ ID NO: 58, and the H-FR4 may comprise the amino acid sequence shown in SEQ ID NO: 59.
[0154] For example, the H-FR1 may comprise the amino acid sequence shown in any one of SEQ ID NO:4, SEQ ID NO:12, SEQ ID NO:19, SEQ ID NO:34 and SEQ ID NO:38, the H-FR2 may comprise the amino acid sequence shown in any one of SEQ ID NO:5, SEQ ID NO:13, SEQ ID NO:20, SEQ ID NO:25, SEQ ID NO:30 and SEQ ID NO:35, the H-FR3 may comprise the amino acid sequence shown in any one of SEQ ID NO:6, SEQ ID NO:14, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:36 and SEQ ID NO:40, and the H-FR4 may comprise the amino acid sequence shown in any one of SEQ ID NO:7, SEQ ID NO:15 and SEQ ID NO:39.
[0155] In the present application, the antibody or antigen-binding fragment may be a VHH. For example, the VHH may comprise the amino acid sequence shown in any one of SEQ ID NO: 8, SEQ ID NO: 16, SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 32, SEQ ID NO: 37, and SEQ ID NO: 41.
[0156] In the present application, the antibody or antigen-binding fragment thereof may include a heavy chain constant region. For example, the heavy chain constant region refers to a region comprising at least three heavy chain constant domains, CH1, CH2, and CH3. Non-limiting exemplary heavy chain constant regions include γ, δ, and α. Non-limiting exemplary heavy chain constant regions also include ε and μ. Each heavy chain constant region corresponds to an antibody isotype. For example, an antibody comprising a γ constant region is an IgG antibody, an antibody comprising a δ constant region is an IgD antibody, and an antibody comprising an α constant region is an IgA antibody. In addition, an antibody comprising a μ constant region is an IgM antibody, and an antibody comprising an ε constant region is an IgE antibody. Certain isotypes can be further subdivided into subclasses. For example, IgG antibodies include, but are not limited to, IgG1 (comprising a γ1 constant region), IgG2 (comprising a γ2 constant region), IgG3 (comprising a γ3 constant region), and IgG4 (comprising a γ4 constant region) antibodies; IgA antibodies include, but are not limited to, IgA1 (comprising an α1 constant region) and IgA2 (comprising an α2 constant region) antibodies; and IgM antibodies include, but are not limited to, IgM1 and IgM2.
[0157] In the present application, the antibody heavy chain constant region may be derived from IgG. In the present application, the isolated antigen-binding protein may include an antibody heavy chain constant region, and the antibody heavy chain constant region may be derived from human IgG. In the present application, the isolated antigen-binding protein may include an antibody heavy chain constant region, and the antibody heavy chain constant region may be derived from IgG4. In the present application, the heavy chain constant region of the antigen-binding protein may include the Fc region of IgG. For example, the antibody heavy chain constant region may include the amino acid sequence shown in SEQ ID NO:44.
[0158] Bispecific antibodies or antigen-binding fragments thereof
[0159] In another aspect, the present application also provides bispecific antibodies or antigen-binding fragments thereof, comprising a first binding domain that specifically binds to the CD39 protein, wherein the first binding domain comprises the CD39-targeting antibody or antigen-binding fragment thereof described herein. That is, the CD39-targeting antibody or antigen-binding fragment thereof described herein can also form a bispecific antibody structure with antibodies targeting other targets.
[0160] In the present application, the bispecific antibody or antigen-binding fragment thereof comprises the VHH that specifically binds to CD39 as described herein.
[0161] In the present application, the second binding domain of the bispecific antibody or antigen-binding fragment thereof can target PD-L1. For example, the second binding domain can be an antibody or antigen-binding fragment thereof that targets PD-L1.
[0162] In the present application, the PD-L1 antibody or antigen-binding fragment thereof may comprise HCDR1, HCDR2, and HCDR3, wherein the HCDR1 may comprise the amino acid sequence set forth in SEQ ID NO: 45, the HCDR2 may comprise the amino acid sequence set forth in SEQ ID NO: 46, and the HCDR3 may comprise the amino acid sequence set forth in SEQ ID NO: 47. In the present application, the PD-L1 antibody or antigen-binding fragment thereof may comprise LCDR1, LCDR2, and LCDR3, wherein the LCDR1 may comprise the amino acid sequence set forth in SEQ ID NO: 49, the LCDR2 may comprise the amino acid sequence set forth in SEQ ID NO: 50 (GNS), and the LCDR3 may comprise the amino acid sequence set forth in SEQ ID NO: 51.
[0163] In the present application, the PD-L1 antibody or antigen-binding fragment thereof may comprise a VH, which may comprise the amino acid sequence shown in SEQ ID NO: 48. In the present application, the PD-L1 antibody or antigen-binding fragment thereof may comprise a VL, which may comprise the amino acid sequence shown in SEQ ID NO: 52.
[0164] In the present application, the PD-L1 antibody or antigen-binding fragment thereof may comprise an antibody heavy chain constant region and an antibody light chain constant region.
[0165] In the present application, the CD39 targeting portion of the bispecific antibody or antigen-binding fragment thereof can be directly or indirectly connected to the PD-L1 targeting portion. For example, the N-terminus of the CD39 targeting portion can be directly or indirectly connected to the C-terminus of the PD-L1 targeting portion. For example, the C-terminus of the CD39 targeting portion can be directly or indirectly connected to the N-terminus of the PD-L1 targeting portion. For example, they can be connected through a linker. For example, the linker can comprise an amino acid sequence represented by (G4S)n, wherein n is a positive integer from 1 to 10. For example, n is 3.
[0166] In the present application, the bispecific antibody or antigen-binding fragment thereof may comprise a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain may comprise the heavy chain variable region of the PD-L1 antibody or antigen-binding fragment thereof, the heavy chain constant region of the PD-L1 antibody or antigen-binding fragment thereof, and the VHH that specifically binds to CD39, and the second polypeptide chain may comprise the light chain variable region and light chain constant region of the PD-L1 antibody or antigen-binding fragment thereof.
[0167] In the present application, the bispecific antibody or antigen-binding fragment thereof may comprise a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain may comprise the heavy chain variable region of the PD-L1 antibody or antigen-binding fragment thereof, the heavy chain constant region of the PD-L1 antibody or antigen-binding fragment thereof, a linker, and the VHH that specifically binds to CD39, and the second polypeptide chain may comprise the light chain variable region and light chain constant region of the PD-L1 antibody or antigen-binding fragment thereof.
[0168] In the present application, the bispecific antibody or antigen-binding fragment thereof may comprise a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain may comprise, from N-terminus to C-terminus, the heavy chain variable region of the PD-L1 antibody or antigen-binding fragment thereof, the heavy chain constant region of the PD-L1 antibody or antigen-binding fragment thereof, a linker, and the VHH that specifically binds to CD39, and the second polypeptide chain comprises the light chain variable region and light chain constant region of the PD-L1 antibody or antigen-binding fragment thereof.
[0169] In the present application, the bispecific antibody or antigen-binding fragment thereof may comprise a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain may comprise, from N-terminus to C-terminus, the VHH that specifically binds to CD39, a linker, the heavy chain variable region of the PD-L1 antibody or antigen-binding fragment thereof, and the heavy chain constant region of the PD-L1 antibody or antigen-binding fragment thereof, and the second polypeptide chain may comprise the light chain variable region and light chain constant region of the PD-L1 antibody or antigen-binding fragment thereof.
[0170] In the present application, the bispecific antibody or antigen-binding fragment thereof may comprise two first polypeptide chains and two second polypeptide chains.
[0171] CAR-T cell autosecretory CD39 antigen binding protein
[0172] On the other hand, the CAR-T cells can also be used to autosecrete the CD39-targeting antigen binding protein described in this application to enhance the proliferation effect of CAR-T cells and / or the tumor cell killing effect. For example, by designing a cleavage peptide, the sequence encoding the CAR and the sequence encoding the CD39 antibody can be designed in the same vector, thereby achieving CAR-T cell autosecretion of the CD39 antibody described in this application. In the present application, the CAR can be a CAR targeting MSLN, for example, the CAR can include a signal peptide, an antigen binding protein targeting MSLN, a hinge region, a transmembrane region, a co-stimulatory region and / or an intracellular signaling region. For example, the signal peptide can be a CD8 signal peptide, for example, the CD8 signal peptide can include the amino acid sequence shown in SEQ ID NO: 66. For example, the antigen binding protein targeting MSLN can be a VHH, for example, the VHH can include the amino acid sequence shown in SEQ ID NO: 67. For example, the hinge region can be a CD8 hinge region, for example, the CD8 hinge region can include the amino acid sequence shown in SEQ ID NO: 68. For example, the transmembrane region can be a CD8 transmembrane region, for example, the CD8 transmembrane region can comprise the amino acid sequence shown in SEQ ID NO: 69. For example, the costimulatory region can be a 4-1BB costimulatory region, for example, the 4-1BB costimulatory region can comprise the amino acid sequence shown in SEQ ID NO: 70. For example, the intracellular signaling region can be a CD3ζ intracellular signaling region, for example, the CD3ζ intracellular signaling region can comprise the amino acid sequence shown in SEQ ID NO: 71.
[0173] Polypeptides, nucleic acid molecules, vectors, cells, drug combinations, pharmaceutical compositions and preparation methods
[0174] On the other hand, the present application also provides a polypeptide comprising the antibody or antigen-binding fragment thereof, or the bispecific antibody or antigen-binding fragment thereof.
[0175] In another aspect, the present application further provides one or more isolated nucleic acid molecules that can encode the antibody or antigen-binding fragment thereof, or the bispecific antibody or antigen-binding fragment thereof described herein. For example, each of the one or more nucleic acid molecules can encode the entire antibody or antigen-binding fragment thereof, or a portion thereof (e.g., one or more of HCDR1-3, LCDR1-3, VL, VH, light chain, or heavy chain).
[0176] The nucleic acid molecules described herein can be isolated. For example, they can be produced or synthesized by the following methods: (i) in vitro amplification, such as by polymerase chain reaction (PCR) amplification, (ii) by cloning and recombination, (iii) purification, such as by enzyme digestion and gel electrophoresis fractionation, or (iv) synthesis, such as by chemical synthesis. In some embodiments, the isolated nucleic acid is a nucleic acid molecule prepared by recombinant DNA technology.
[0177] In the present application, nucleic acids encoding the antibodies or antigen-binding fragments thereof can be prepared by a variety of methods known in the art, including but not limited to, restriction fragment manipulation or overlap extension PCR using synthetic oligonucleotides. For specific procedures, see Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausube et al., Current Protocols in Molecular Biology, Greene Publishing and Wiley-Interscience, New York NY, 1993.
[0178] In the present application, the nucleic acid molecule may further comprise a nucleic acid molecule encoding another protein. For example, the other protein may be a CAR.
[0179] In another aspect, the present application provides one or more vectors comprising one or more nucleic acid molecules described herein. Each vector may contain one or more of the nucleic acid molecules described herein. Furthermore, the vectors may also contain other genes, such as marker genes that allow selection of the vector in appropriate host cells and under appropriate conditions. Furthermore, the vectors may also contain expression control elements that allow for proper expression of the coding region in an appropriate host. Such control elements are well known to those skilled in the art and may include, for example, promoters, ribosome binding sites, enhancers, and other control elements that regulate gene transcription or mRNA translation. In certain embodiments, the expression control sequences are adjustable elements. The specific structure of the expression control sequences may vary depending on the function of the species or cell type, but generally include 5' non-transcribed sequences and 5' and 3' non-translated sequences involved in transcription and translation initiation, respectively, such as a TATA box, a capping sequence, a CAAT sequence, etc. For example, the 5' non-transcribed expression control sequence may include a promoter region, which may include a promoter sequence functionally linked to a nucleic acid for transcriptional control. The one or more nucleic acid molecules described herein may be operably linked to the expression control elements.
[0180] The vector may include, for example, a plasmid, a cosmid, a virus, a phage or other vectors commonly used in, for example, genetic engineering. For example, the vector is an expression vector.
[0181] In the present application, the vector may further comprise nucleic acid molecules encoding other proteins. For example, the vector may further comprise nucleic acid molecules encoding chimeric antigen receptors (CARs). For example, the CARs may target any known target. For example, the CARs may target MSLN (mesothelin).
[0182] In another aspect, the present application provides cells, which may comprise an antibody or antigen-binding fragment thereof described herein, a bispecific antibody or antigen-binding fragment thereof described herein, a nucleic acid molecule described herein, and / or a vector described herein. The cell may be a host cell. In certain embodiments, each or each host cell may comprise one or more nucleic acid molecules or vectors described herein. In certain embodiments, each or each host cell may comprise multiple (e.g., 2 or more) or multiple (e.g., 2 or more) nucleic acid molecules or vectors described herein. For example, the vectors described herein may be introduced into the host cells, such as eukaryotic cells, such as cells from plants, fungi or yeast cells, etc. The vectors described herein may be introduced into the host cells by methods known in the art, such as electroporation, lipofectine transfection, lipofectamin transfection, etc.
[0183] In the present application, the cell may include an immune cell. In certain embodiments, the cell may include a T cell, a B cell, a natural killer cell (NK cell), a macrophage, an NKT cell, a monocyte, a dendritic cell, a granulocyte, a lymphocyte, a leukocyte, a peripheral blood mononuclear cell, an embryonic stem cell, a lymphocyte progenitor cell and / or a pluripotent stem cell.
[0184] In the present application, the cell may express the antibody or antigen-binding fragment thereof described herein, or the bispecific antibody or antigen-binding fragment thereof described herein. In certain embodiments, the cell may further comprise and / or express other proteins. For example, the cell may further comprise and / or express a CAR.
[0185] On the other hand, the present application also provides a drug combination, which may include the following components: (1) the antibody or antigen-binding fragment thereof described in the present application, or the bispecific antibody or antigen-binding fragment thereof described in the present application; and (2) cells. For example, the cells may be modified cells or unmodified cells. For example, the cells may be immune cells. For example, the cells may be T cells. In the drug combination, component (1) and component (2) may be placed separately or mixed to form a mixture. Component (1) can help improve the function of component (2), for example, promoting the proliferation of component (2).
[0186] On the other hand, the present application also provides a pharmaceutical composition, which may include the antibody or its antigen-binding fragment, the bispecific antibody or its antigen-binding fragment, the nucleic acid molecule, the vector, the cell and / or the drug combination, and optionally a pharmaceutically acceptable carrier.
[0187] In certain embodiments, the pharmaceutical composition can include one or more (pharmaceutically effective) carriers, stabilizers, excipients, diluents, solubilizers, surfactants, emulsifiers and / or preservatives. The acceptable ingredients of the composition are preferably non-toxic to the recipient at the dosage and concentration used. The pharmaceutical composition of the present invention can include liquid, frozen and lyophilized compositions.
[0188] In certain embodiments, the pharmaceutically acceptable carrier can include any and all solvents, dispersion media, coatings, isotonic agents, and absorption delaying agents that are compatible with pharmaceutical administration and are generally safe, non-toxic, and neither biologically nor otherwise undesirable.
[0189] In certain embodiments, the pharmaceutical composition can comprise parenteral, transdermal, intracavitary, intraarterial, intrathecal and / or intranasal administration or direct injection into a tissue. For example, the pharmaceutical composition can be administered to a patient or subject by infusion or injection. In certain embodiments, the administration of the pharmaceutical composition can be carried out in different ways, such as intravenous, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration.
[0190] In another aspect, the present application also provides a method for preparing the antibody or antigen-binding fragment thereof and / or bispecific antibody or antigen-binding fragment thereof. The method may include culturing the cell under conditions that allow expression of the antibody or antigen-binding fragment thereof and / or bispecific antibody or antigen-binding fragment thereof.
[0191] use
[0192] On the other hand, the present application also provides the use of the antibody or antigen-binding fragment thereof, the bispecific antibody or antigen-binding fragment thereof, the nucleic acid molecule, the cell, the drug combination, or the pharmaceutical composition in the preparation of a drug for preventing and / or treating a disease and / or condition.
[0193] On the other hand, the present application also provides a method for preventing and / or treating a disease and / or condition, comprising administering the antibody or antigen-binding fragment thereof, the bispecific antibody or antigen-binding fragment thereof, the nucleic acid molecule, the cell, the drug combination, or the pharmaceutical composition to a subject in need.
[0194] On the other hand, the present application also provides the antibody or antigen-binding fragment thereof, the bispecific antibody or antigen-binding fragment thereof, the nucleic acid molecule, the cell, the drug combination, or the pharmaceutical composition, which is used to prevent and / or treat diseases and / or conditions.
[0195] In certain embodiments, the disease and / or condition may comprise a tumor.
[0196] In certain embodiments, the tumor may include a solid tumor and / or a hematological tumor.
[0197] In certain embodiments, the tumor may include a tumor affected by CD39 activity. For example, the tumor may be a tumor that overexpresses CD39. For example, the tumor may be colon cancer.
[0198] In the present application, the subject may include a human or a non-human animal.
[0199] In another aspect, the present application provides a kit or drug delivery device comprising the antibody or antigen-binding fragment thereof, the bispecific antibody or antigen-binding fragment thereof, the nucleic acid molecule, the cell, the drug combination, or the pharmaceutical composition. The kit can be used to detect the presence and / or content of CD39.
[0200] Without intending to be bound by any theory, the following examples are merely intended to illustrate the antibodies or antigen-binding fragments thereof, their preparation methods and uses, and are not intended to limit the scope of the invention.
[0201] Example
[0202] Example 1 Screening of Nanobodies Targeting Human CD39
[0203] 1.1 Alpaca immunization and construction of phage display immune nanoantibody library
[0204] We purchased human CD39-His protein (CD9-H52H4) from ACRO and commissioned Chengdu Apak Biotechnology Co., Ltd. to immunize alpacas and build a library according to the known protocols in the art. The first immunization dose was 0.5 mg protein, and the next three immunizations used 0.25 mg protein. After the third and fourth immunizations, 50 mL of peripheral blood was collected for standby use, and a small amount of serum was separated. The immune effect was detected by ELISA. Finally, the third and fourth immunization titers reached more than 1:16000 (coated antigen 2 ug / mL, OD positive value greater than 2.0), which met the library construction requirements. PBMC was isolated and RNAiso Plus reagent was used to extract total RNA from triple and quadruple PBMCs. PrimeScript TM II 1 st The extracted RNA was reverse transcribed into cDNA using the Strand cDNA Synthesis Kit (6210A, Takara). Following protocols known in the art, the variable region (VHH) of the heavy chain antibody was amplified by two rounds of nested PCR. The target fragment was recovered by gel extraction and cloned into the phage display vector pComb3XSS using the restriction endonuclease SfiI. After desalting, the plasmid was electroporated into electrocompetent Escherichia coli TG1 to construct a phage display nanobody library, and the library was evaluated for diversity. The antibody library was plated with gradient dilutions, and the library capacity was calculated to be 1.30×10 9 48 monoclonal clones were randomly selected for sequencing, and all were correctly inserted. Except for 5 monoclonal clones identified as non-monoclonal clones, the CDRs of the remaining sequences were not completely consistent. The sense mutation rate was determined to be 89.6% (43 / 48), and the diversity was 1.16×10 9 .
[0205] 1.2 Sequence selection of antibodies targeting human CD39
[0206] Plates were coated with 10 μg / ml of human CD39-His protein (CD9-H52H4, ACRO) and incubated overnight at 4°C. The following day, the plates were washed three times with 1×PBST (PBS containing 0.05% Tween 20), blocked with 0.5% BSA for 2 hours at room temperature, and washed three times with 1×PBST. 100 μl of phage (from the phage-displayed immune nanobody library constructed in Example 1) was added for screening. One hour later, the plates were washed 15 times with 1×PBST to remove phage that did not bind to the antigen. Finally, the plates were eluted with Glycine-HCl (pH 2.2) at 100 μl / well and neutralized with Tris-HCl (pH 8.0). Half of the eluted phage was used to infect TG1 cells in the logarithmic growth phase. Half an hour later, the cells were superinfected with M13KO7 cells and cultured overnight. The phage were precipitated the following day for the next round of screening. A similar screening process was repeated for three rounds. In the second round, 5 μg / ml human CD39-His positive screen was used, and 1× PBST was used for washing 30 times. In the third round, 1 μg / ml human CD39-His positive screen was used, and 1× PBST was used for washing 50 times. After that, the specific enrichment of the antibody was detected by Pool ELISA.
[0207] 1.3 Screening of specific monoclonal antibodies using phage enzyme-linked immunosorbent assay (ELISA)
[0208] Single colonies were picked and cultured overnight in 12 96-well deep-well plates to produce phage. The next day, 384-well plates were coated with human CD39-His, IgG1-Fc, and 0.2% BSA. After washing three times with 1× PBST (PBS containing 0.05% Tween 20), the plates were blocked with 0.5% BSA for 2 hours at room temperature, and washed three times with 1× PBST. 100 μl of phage supernatant was added and the plates were incubated for 1 hour. After washing, anti-M13-HRP (SinoBiological, Catalog No. 11973-MM05T-H) was added and incubated for 1 hour. After washing, TMB colorimetric solution (Invitrogen, Catalog No. 002023) was added. After 3-5 minutes, 2M phosphoric acid was added to terminate the color reaction, and the OD450 value was read. A well was considered positive when the OD value of the sample well was at least 5 times that of the control well. The amino acid sequences of each clone were analyzed using sequence alignment software, and a total of 419 positive sequences were obtained. Based on the differences in CDR3, 90 candidate sequences with large CDR differences were selected for subsequent expression identification.
[0209] Example 2 Evaluation of in vitro affinity and enzyme activity inhibition function of CD39 nanobody
[0210] 2.1 Expression and purification of bivalent nanobodies in Expi293F
[0211] The nucleotide sequences of 90 nanobodies obtained by sequence analysis and the control antibody H5L5 (patent CN112714768A, VH sequence is SEQ ID NO: 42, VL sequence is SEQ ID NO: 43) were compared with IgG4 F C The sequence (SEQ ID NO: 44) was subcloned into the eukaryotic expression vector pcDNA3.4, then transfected into Expi293F cells and cultured for 5 days to produce the bivalent antibody. The supernatant was collected and purified using Protein A (GenScript, Cat. No. L00695-80).
[0212] 2.2 Fortebio tested the affinity of CD39 nanoantibodies to human CD39 protein
[0213] The CD39 antibody was diluted to 100 nM and added to a 384-well plate. The human CD39-His antigen (ACRO, CD9-H52H4) was diluted to 100 nM, diluted 2-fold in a total of 7 gradients, and added to a 384-well plate. An AHC probe (Sartorius, Cat. No. 18-5060) was used with an association time of 180 seconds, a dissociation time of 360 seconds, a baseline of 60 seconds, and three regeneration cycles of 5 seconds each. The binding-dissociation curves were then fitted using software to calculate the affinity of the antibodies. The results, as shown in Figure 1 and Table 1, show that the six nanobodies can bind to the human CD39 protein with high affinity. Among them, the amino acid sequence of VHH of B391-F04 is SEQ ID NO: 8, the amino acid sequence of VHH of B391-A04 is SEQ ID NO: 16, the amino acid sequence of VHH of B391-G06 is SEQ ID NO: 21, the amino acid sequence of VHH of B393-D07 is SEQ ID NO: 27, the amino acid sequence of VHH of B39C6-G06 is SEQ ID NO: 32, and the amino acid sequence of VHH of B39C8-G05 is SEQ ID NO: 37.
[0214] Table 1
[0215] 2.3 Flow cytometry detection of the binding of CD39 nanobody to human CD39 on cell surface
[0216] Normally cultured CD39-CHO overexpressing cells and CHO wild-type cells were digested and centrifuged, and then resuspended in PBS containing 0.1% BSA; 4E4 cells were added to each well of a 96-well pointed bottom plate, and 30 μl was added to each well; CD39 antibody was prepared to 90 ug / mL (60 uL system), and diluted 3-fold in a gradient, with no antibody added to the last gradient; 30 uL of the diluted antibody was added to the corresponding cell wells, mixed, and incubated at 4°C for 1 hour; 120 uL buffer was added, and the cells were centrifuged at 500g for 5 minutes; the supernatant was discarded, gently blotted on a paper towel, the cells were fluffed with a vortex, and anti-human IgG-FC dylight650 secondary antibody (1:200) was added, 30 uL per well, and incubated at 4°C for 30 minutes; 150 uL buffer was added, and the cells were centrifuged at 500g for 5 minutes, and then washed once; the supernatant was removed, and the cells were fluffed and resuspended in 30 uL buffer for detection. The results are shown in Figure 2 , and the six nanobodies can specifically bind to human CD39 membrane protein.
[0217] 2.4 ELISA detection of binding of CD39 antibodies to human, mouse, and cynomolgus monkey CD39 proteins
[0218] ACRO human, mouse, and cynomolgus macaque CD39 proteins (2ug / mL) were coated in 30uL / well plates at 4°C overnight. The next day, the coated plates were washed three times with PBS, blocked with 60uL / well of 5% milk, and incubated at 400rpm for 2h at room temperature. The plates were then washed three times with PBST, and CD39 antibodies were diluted with PBS to a maximum concentration of 200nM, followed by a three-fold dilution. No antibody was added to the last well, and 30uL / well of the diluted antibody was added to a 384-well plate and incubated at 400rpm for 1h at room temperature. The plates were then washed three times with PBST, and 25uL / well of a 1:10,000 dilution of anti-human IgG-HRP secondary antibody was added, incubated at 400rpm for 30min at room temperature. The plates were washed seven times with PBST, and TMB was added for color development (25uL / well). After an appropriate time, the plate was blocked with stop buffer (25uL / well) and read at 450nm. As shown in Figure 3, all six nanobodies bound to mouse and cynomolgus macaque CD39 proteins to some extent.
[0219] 2.5 Detection of the enzyme activity inhibition function of CD39 antibodies at the protein level
[0220] Prepare CD39 antibody with Assay buffer to a maximum concentration of 1000nM, and dilute the antibody three times in a 3-fold gradient; prepare CD39-His protein to 50nM, add 5uL of CD39 protein to each well (final concentration 5nM), add 45uL of diluted CD39 antibody, and incubate at 37℃ for 120min; then add 50ul of 1000uM ATP to each well and incubate at 37℃ for 1h; take 25uL to a black 384-well plate and add an equal volume of Reagent 25uL / well, mix well and shake on a shaker for 2 minutes, then place at room temperature for 10 minutes to allow the fluorescent signal to stabilize, then read the reading, calculate the enzyme activity inhibition rate according to the following formula, and plot it. The results are shown in Figure 4. All six nanoantibodies can inhibit CD39 protease activity to a certain extent.
[0221] CD39 inhibition rate calculation formula:
[0222] 2.6 Detection of the enzyme activity inhibition function of CD39 antibodies at the cellular level
[0223] When SK-MEL-28 cells reached about 80% confluence, the cells were digested and plated at 1.5E4 cells / 100uL / well, and cultured in a 37°C incubator overnight. CD39 antibody was prepared to a maximum concentration of 1000nM and the antibody was diluted 3-fold. 50ul of the gradient diluted antibody was added to each well of the overnight cultured cells, and the cells were incubated at 37°C for 30min. 50ul of 300uM ATP was added to each well, and the cells were incubated at 37°C for 1h. 25uL was taken and placed in a black 384-well plate, and an equal volume of Add 25 μL of reagent per well, mix thoroughly, and shake on a shaker for 2 minutes. Then, incubate at room temperature for 10 minutes to allow the fluorescence signal to stabilize. Read the sample and calculate the enzyme inhibition rate according to the following formula. The results are plotted. As shown in Figure 5, all six nanobodies inhibited CD39 trypsin activity to some extent. Overall, compared to the control antibody H5L5, the B391-F04 antibody exhibited significant advantages in both cellular and protein-level enzyme inhibition.
[0224] CD39 inhibition rate calculation formula:
[0225] Example 3 Detection of the Proliferation-Promoting Effect of CD39-F04 Antibody on PBMC-Derived T Cells
[0226] Frozen PBMCs were revived and activated with CD3 / CD28 magnetic beads. 5E5 cells were plated per well. B391-F04 and H5L5 antibodies were diluted to final concentrations of 1000, 333, and 111 nM, respectively. After addition, the cells were incubated at 37°C for 30 minutes. ATP was then added to a final concentration of 1000 uM. After four days of co-culture, the cells were counted. As shown in Figure 6, different concentrations of B391-F04 and H5L5 antibodies promoted T cell proliferation to some extent in the presence of ATP, with no significant difference between the two.
[0227] Example 4 Detection of expression of inhibitory markers on the surface of tumor cells after stimulation by MSLN-CART expressing autocrine CD39 antibodies
[0228] MSLN-CART (see Figure 7 for a simplified structure) cells that do not secrete CD39 or autosecrete B391-F04 and H5L5 antibodies (SEQ ID NO: 61 and SEQ ID NO: 62) were co-cultured with SKOV3-MSLN cells that overexpress MSLN. After 4 days, the expression of inhibitory markers (PD-1, CD39, and Tim-3) on the surface of CAR-T cells was detected. The results are shown in Figure 8. Compared with the non-secreting control group, the experimental group can significantly reduce the expression of CD39 on the surface of CART cells, and the effect of B391-F04 is more obvious. In addition, the expression of PD-1 and Tim-3 exhaustion markers of CART cells was not upregulated.
[0229] Example 5 Humanization and functional identification of CD39 antibody
[0230] 5.1 Final humanization of B391-F04 and affinity determination
[0231] Humanization was performed based on the B391-F04 sequence (SEQ ID NO: 41) to construct pcDNA3.4-B391-F04-IgG4 F C Eukaryotic expression plasmids were used to produce antibody proteins by transient transfection of Expi293F and purified by Protein A.
[0232] B391-F04, B391-hF04 (VHH sequence is SEQ ID NO: 41), and H5L5 were diluted to 100 nM and added to a 384-well plate. Human CD39-His antigen (ACRO, CD9-H52H4) was diluted 2-fold, with a total of 7 gradients, and added to a 384-well plate. An AHC probe (Sartorius, Cat. No. 18-5060) was used, with an association time of 180 seconds, a dissociation time of 300 seconds, a baseline of 60 seconds, and three regeneration cycles of 5 seconds each. The binding-dissociation curves were then fitted using software to calculate the affinity of the antibodies. The results are shown in Figure 9 and Table 2. The affinities of the humanized and unhumanized sequences were similar, both superior to the H5L5 control antibody.
[0233] Table 2
[0234] 5.2 Detection of the enzyme inhibitory function of B391-hF04 humanized antibody at the protein level
[0235] Prepare CD39 antibody with Assay buffer to a maximum concentration of 100 nM, and dilute the antibody 3-fold in 9 gradients; prepare CD39-His protein to 50 nM, add 5 uL of CD39 protein to each well (final concentration 5 nM), add 45 uL of diluted CD39 antibody, and incubate at 37°C for 120 min; then add 50 ul of 1000 uM ATP to each well and incubate at 37°C for 1 h; take 25 uL to a black 384-well plate and add an equal volume of Add 25 μL of Reagent to each well, mix thoroughly, and shake for 2 minutes. Then, incubate at room temperature for 10 minutes to allow the fluorescence signal to stabilize. Read the fluorescence signal and calculate the enzyme inhibition rate according to the following formula. The results are shown in Figure 10. Compared to the control antibody H5L5, no significant differences were observed between the three.
[0236] CD39 inhibition rate calculation formula:
[0237] 5.3 Detection of the enzyme inhibitory function of B391-hF04 antibody at the cellular level
[0238] When SK-MEL-28 cells reached about 80% confluence, the cells were digested and plated at 1.5E4 cells / 100uL / well, and cultured in a 37°C incubator overnight. CD39 antibody was prepared to a maximum concentration of 100nM, and the antibody was diluted 3-fold in 9 gradients. 50ul of the gradient diluted antibody was added to each well of the overnight cultured cells and incubated at 37°C for 30min. 50ul of 300uM ATP was added to each well and incubated at 37°C for 1h. 25uL was taken and placed in a black 384-well plate, and an equal volume of Add 25 μL of Reagent to each well, mix thoroughly, and shake for 2 minutes. Then, incubate at room temperature for 10 minutes to allow the fluorescence signal to stabilize. Read the fluorescence readings and calculate the enzyme inhibition rate according to the following formula. The results are shown in Figure 11. Taking into account experimental error within each group, no significant differences were observed between the three assays compared to the control antibody, H5L5.
[0239] CD39 inhibition rate calculation formula:
[0240] Example 6 Detection of the effect of humanized CD39 antibody on the proliferation improvement of CAR-T cells
[0241] The frozen MSLN-CART (wherein the amino acid sequence of CAR is as shown in SEQ ID NO: 60) was revived and activated with CD3 / CD28 magnetic beads. 5E5 cells were plated per well, and B391-hF04 and H5L5 antibodies were diluted to a final concentration of 333 and 111 nM. After adding the cells, they were incubated at 37 ° C for 30 minutes, and then ATP was added at a final concentration of 1000 uM. After culturing for 4 days, the cells were counted. As shown in Figure 12, in the presence of high concentrations of ATP, B391-hF04 significantly improved the proliferation of CAR-T cells compared to the H5L5 control antibody.
[0242] Example 7 Design, molecular cloning and expression identification of bispecific antibodies
[0243] The antibody targeting PD-L1 (YN035) is an IgG, while the antibody targeting CD39 is a nanobody. On the one hand, PD-L1 is mainly expressed on the surface of tumor cells, with a small amount expressed on the surface of DC cells. CD39 is mainly expressed on tumors and immune cells. If both are on the same cell, theoretically, the PD-L1 / CD39 bispecific antibody forms cross-links on the cell surface, which can exert a greater inhibitory effect. If only PD-L1 is expressed on the surface of tumor cells, it can spatially shorten the distance to immune cells and exert a stronger immune function. Therefore, when designing bispecific antibodies, the PD-L1 / CD39 bispecific antibody needs to retain a bivalent binding activity similar to that of the parent antibody. In addition, considering that CD39 is significantly upregulated on immune cells in the tumor microenvironment, the Fc of IgG4 is used to give it weaker ADCC and CDC activity. The specific design is shown in Figure 13, in which the nanoantibody is connected to the N-terminus and C-terminus of the heavy chain of YN035 (the sequence of HCDR1 is SEQ ID NO: 45, the sequence of HCDR2 is SEQ ID NO: 46, the sequence of HCDR3 is SEQ ID NO: 47, the sequence of VH is SEQ ID NO: 48, the sequence of LCDR1 is SEQ ID NO: 49, the sequence of LCDR2 is SEQ ID NO: 50 (GNS), the sequence of LCDR3 is SEQ ID NO: 51, and the sequence of VL is SEQ ID NO: 52), respectively, wherein the flexible linker is (G4S)n, where n = 1, 2, 3, 4, and the bispecific antibodies are named YN035-n-hF04 and hF04-YN035. Using conventional molecular cloning methods, the light and heavy chains of the bispecific antibody sequences were loaded into the eukaryotic expression vector pcDNA3.4. The light and heavy chain expression plasmids were then transfected into Expi293F cells at a ratio of 2:3. After culturing in a cell culture incubator for 5 days, the supernatant was collected and purified using Protein A (GenScript, Catalog No.: L00695-80) and Superdex200.
[0244] Purity analysis was performed using a SEC chromatography column. The specific process was as follows: a high performance liquid chromatograph (Agilent Technologies 1200 Series) was opened. Purified water was first used to remove the air from the system line at a flow rate of 2 ml / min. After flushing for 30 min, a SET-C SEC-300 (Sepax, catalog number: 2F36102) was connected to the instrument. The column was first flushed with purified water at a flow rate of 0.5 ml / min for 1 h, and then flushed with PBS at a flow rate of 1 ml / min for 1 h. The sample to be tested was diluted to 1 mg / ml, 100 μL of Marker and the diluted sample were added to the sample loading tank tube, the marker loading volume was set to 6 μl, the diluted loading volume to be tested was set to 10 μL, the flow rate was 1 ml / min, and the run was 20 min for sample detection and analysis. The results are shown in Figure 14. The purity of the constructed bispecific antibodies was good. The YN035-3-hF04 bispecific antibody was used as an example to detect the in vivo efficacy.
[0245] Example 8 Verification of the in vivo efficacy of bispecific antibodies
[0246] MC38 cells were cultured at 1×10 5 The cells were inoculated into the right side of C57BL / 6-hCD39 / hCD73 humanized mice at a concentration of 0.1 mL. The tumors were grown to about 10-20 mm. 2 The mice were randomly divided into groups based on tumor volume. All groups were administered intraperitoneally, once every three days for six consecutive doses, with the experiment terminated five days after the last dose. Mouse body weight and tumor volume were measured three times a week during the dosing and observation period, and the measurements were recorded. At the conclusion of the experiment, the animals were euthanized. The results are shown in Figure 15. In this animal model, hF04 significantly inhibited tumor growth compared to the H5L5 control antibody. The YN035-3-hF04 dual antibody also exhibited significant tumor inhibition compared to the control monoclonal antibody and the combined control group.
[0247] Example 9 Verification of the in vivo efficacy of autocrine antibody CAR-T and antibody combined with blank CAR-T
[0248] SKOV3-MSLN hi -PDL1 mid -CD39 hi Ovarian cancer cells were expressed at 3×10 6 The concentration of 0.2 mL was inoculated into the right side of the B-NDG mouse subcutaneously. 2, and then randomly divided into 9 groups, and the MSLN-CART (structural diagram shown in Figure 16) cells that secrete MockT, do not secrete antibodies or autosecrete B391-hF04, YN035 (scFv), and B391-hF04 + YN035 (scFv) antibodies were injected into the tail vein for a total of 1 dose. At the same time, the combined drug group was injected into the tail vein, administered once every three days, and administered 8 times in a row. Among them, the amino acid sequence of MSLN-CART is shown in SEQ ID NO: 60, the amino acid sequence of MSLN-CART-B391-hF04 is shown in SEQ ID NO: 63, the amino acid sequence of MSLN-CART-YN035 (scFv) is shown in SEQ ID NO: 64, and the amino acid sequence of MSLN-CART-B391-hF04-T2A-YN035 (scFv) is shown in SEQ ID NO: 65. During the experiment, if any one or more of the following conditions occurred, the experimental animals were euthanized: 1) the tumor was severely damaged and did not scab within 3 days; 2) the animal showed abnormal movement or paralysis; 3) the animal's tumor reached 2000mm 3 . The body weight and tumor volume of the mice were measured three times a week during the administration and observation period, and the measured values were recorded. At the end of the experiment, the animals were euthanized. The results are shown in Figure 17. In this animal model, the MSLN-CART of autocrine B391-hF04, YN035 (scFv), and B391-hF04+YN035 (scFv) antibodies had a significant tumor inhibitory effect, and the tumor inhibitory effect of the autocrine B391-hF04 and YN035 (scFv) antibody experimental groups was significantly better than the combined application of antibodies and blank CAR-T.
Claims
1. An antibody or an antigen-binding fragment thereof, which is capable of specifically binding to CD39 protein and has one or more of the following properties: (1) Can be 1×10 -8 M or lower KD values bind to CD39; (2) ability to bind to human CD39, mouse CD39, or cynomolgus monkey CD39; (3) can effectively inhibit CD39 protease activity; and (4) Ability to inhibit the growth and / or proliferation of tumor cells.
2. The antibody or antigen-binding fragment thereof according to claim 1, comprising at least one CDR in an antibody heavy chain variable region (VH), wherein the VH comprises the amino acid sequence shown in any one of SEQ ID NO:8, SEQ ID NO:16, SEQ ID NO:21, SEQ ID NO:27, SEQ ID NO:32, SEQ ID NO:37 and SEQ ID NO:
41.
3. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 2, comprising a HCDR3 comprising an amino acid sequence as shown in any one of SEQ ID NO: 3, SEQ ID NO: 54 and SEQ ID NO:
55.
4. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, comprising a HCDR3 comprising an amino acid sequence as shown in any one of SEQ ID NO: 3, SEQ ID NO: 11, SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO: 29 and SEQ ID NO:
33.
5. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, comprising a HCDR2, wherein the HCDR2 comprises the amino acid sequence shown in any one of SEQ ID NO: 2, SEQ ID NO: 10, SEQ ID NO: 23 and SEQ ID NO:
28.
6. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, comprising HCDR1, wherein the HCDR1 comprises the amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 53 and SEQ ID NO:
22.
7. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, comprising HCDR1, wherein the HCDR1 comprises the amino acid sequence shown in any one of SEQ ID NO: 1, SEQ ID NO: 9, SEQ ID NO: 17 and SEQ ID NO:
22.
8. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, comprising HCDR1, HCDR2 and HCDR3, wherein the HCDR1, HCDR2 and HCDR3 comprise an amino acid sequence selected from the group consisting of: (1) the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 1, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 2, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 3; (2) The HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 9, and the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: NO:10, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:11; (3) the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 17, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 10, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 18; (4) the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 22, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 23, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 24; (5) the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:22, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:28, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:29; or (6) The HCDR1 comprises the amino acid sequence shown in SEQ ID NO:22, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:28, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:
33.
9. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 8, comprising H-FR1, wherein the C-terminus of the H-FR1 is directly or indirectly connected to the N-terminus of the HCDR1, and the H-FR1 comprises the amino acid sequence shown in SEQ ID NO:
56.
10. The antibody or antigen-binding fragment thereof according to claim 9, wherein the H-FR1 comprises the amino acid sequence shown in any one of SEQ ID NO:4, SEQ ID NO:12, SEQ ID NO:19, SEQ ID NO:34 and SEQ ID NO:
38.
11. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 10, comprising H-FR2, wherein the H-FR2 is located between the HCDR1 and HCDR2, and the H-FR2 comprises the amino acid sequence shown in SEQ ID NO:
57.
12. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 11, wherein the H-FR2 comprises the amino acid sequence shown in any one of SEQ ID NO:5, SEQ ID NO:13, SEQ ID NO:20, SEQ ID NO:25, SEQ ID NO:30 and SEQ ID NO:
35.
13. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 12, comprising H-FR3, wherein the H-FR3 is located between the HCDR2 and the HCDR3, and the H-FR3 comprises the amino acid sequence shown in SEQ ID NO:
58.
14. The antibody or antigen-binding fragment thereof according to claim 13, wherein the H-FR3 comprises the amino acid sequence shown in any one of SEQ ID NO:6, SEQ ID NO:14, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:36 and SEQ ID NO:
40.
15. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 14, comprising H-FR4, wherein the N-terminus of the H-FR4 is connected to the C-terminus of the HCDR3, and the H-FR4 comprises the amino acid sequence shown in SEQ ID NO:
59. 16 . The antibody or antigen-binding fragment thereof according to claim 15 , wherein the H-FR4 comprises the amino acid sequence shown in any one of SEQ ID NO: 7, SEQ ID NO: 15 and SEQ ID NO:
39.
17. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 16, comprising a VH comprising the amino acid sequence shown in any one of SEQ ID NO:8, SEQ ID NO:16, SEQ ID NO:21, SEQ ID NO:27, SEQ ID NO:32, SEQ ID NO:37 and SEQ ID NO:
41.
18. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 17, which is a VHH.
19. The antibody or antigen-binding fragment thereof according to claim 18, wherein the VHH comprises the amino acid sequence shown in any one of SEQ ID NO:8, SEQ ID NO:16, SEQ ID NO:21, SEQ ID NO:27, SEQ ID NO:32, SEQ ID NO:37 and SEQ ID NO:
41.
20. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 19, comprising an antibody heavy chain constant region.
21. The antibody or antigen-binding fragment thereof according to claim 20, wherein the antibody heavy chain constant region is derived from a human IgG constant region.
22. The antibody or antigen-binding fragment thereof according to any one of claims 20-21, wherein the antibody heavy chain constant region is derived from a human IgG4 constant region.
23. The antibody or antigen-binding fragment thereof according to any one of claims 20 to 22, wherein the antibody heavy chain constant region comprises the amino acid sequence shown in SEQ ID NO:
44.
24. The antibody or antigen-binding fragment thereof according to any one of claims 1-23, wherein the antigen-binding fragment comprises Fab, Fab', Fv fragment, F(ab')2, F(ab)2, scFv, di-scFv and / or dAb.
25. The antibody or antigen-binding fragment thereof according to any one of claims 1-24, wherein the antibody is selected from one or more of the following groups: a monoclonal antibody, a chimeric antibody, a humanized antibody, and a fully human antibody.
26. A bispecific antibody or an antigen-binding fragment thereof, comprising a first binding domain that specifically binds to a CD39 protein, wherein the first binding domain comprises the antibody or antigen-binding fragment thereof according to any one of claims 1 to 25.
27. The bispecific antibody or antigen-binding fragment thereof according to claim 26, wherein the first binding domain that specifically binds to CD39 is a VHH that specifically binds to CD39.
28. The bispecific antibody or antigen-binding fragment thereof according to any one of claims 26-27, comprising a second binding domain that specifically binds to a PD-L1 protein. 29 . The bispecific antibody or antigen-binding fragment thereof according to claim 28 , wherein the second binding domain that specifically binds to the PD-L1 protein comprises a PD-L1 antibody or an antigen-binding fragment thereof.
30. The bispecific antibody or antigen-binding fragment thereof of claim 29, wherein the PD-L1 antibody or antigen-binding fragment thereof comprises HCDR1, HCDR2 and HCDR3, wherein the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 45, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 46, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:
47.
31. The bispecific antibody or antigen-binding fragment thereof according to any one of claims 29-30, wherein the PD-L1 antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence shown in SEQ ID NO:
48.
32. The bispecific antibody or antigen-binding fragment thereof according to any one of claims 29 to 31, wherein the PD-L1 antibody or antigen-binding fragment thereof comprises LCDR1, LCDR2 and LCDR3, wherein the LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 49, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 50 (GNS), and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO:
51.
33. The bispecific antibody or antigen-binding fragment thereof according to any one of claims 29 to 32, wherein the PD-L1 antibody or antigen-binding fragment thereof comprises a VL comprising the amino acid sequence shown in SEQ ID NO:
52.
34. The bispecific antibody or antigen-binding fragment thereof according to any one of claims 29-33, wherein the PD-L1 antibody or antigen-binding fragment thereof comprises an antibody heavy chain constant region.
35. The bispecific antibody or antigen-binding fragment thereof according to claim 34, wherein the antibody heavy chain constant region is derived from a human IgG constant region.
36. The bispecific antibody or antigen-binding fragment thereof according to any one of claims 29-35, wherein the PD-L1 antibody or antigen-binding fragment thereof comprises an antibody light chain constant region.
37. The bispecific antibody or antigen-binding fragment thereof according to any one of claims 29 to 36, wherein the C segment of the VHH that specifically binds to CD39 is directly or indirectly connected to the N-terminus of the PD-L1 antibody or antigen-binding fragment thereof.
38. The bispecific antibody or antigen-binding fragment thereof according to any one of claims 29 to 36, wherein the N segment of the VHH that specifically binds to CD39 is directly or indirectly connected to the C-terminus of the PD-L1 antibody or antigen-binding fragment thereof.
39. The bispecific antibody or antigen-binding fragment thereof according to claim 38, wherein the indirect connection comprises connection via a linker.
40. The bispecific antibody or antigen-binding fragment thereof according to claim 39, wherein the linker comprises an amino acid sequence represented by (G4S)n, wherein n is a positive integer of 1-10.
41. The bispecific antibody or antigen-binding fragment thereof according to any one of claims 29-40, comprising a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain comprises the heavy chain variable region of the PD-L1 antibody or antigen-binding fragment thereof, the heavy chain constant region of the PD-L1 antibody or antigen-binding fragment thereof, and the VHH that specifically binds to CD39, and the second polypeptide chain comprises the light chain variable region and the light chain constant region of the PD-L1 antibody or antigen-binding fragment thereof.
42. The bispecific antibody or antigen-binding fragment thereof according to any one of claims 29-41, comprising a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain comprises the heavy chain variable region of the PD-L1 antibody or antigen-binding fragment thereof, the heavy chain constant region of the PD-L1 antibody or antigen-binding fragment thereof, a linker, and the VHH that specifically binds to CD39, and the second polypeptide chain comprises the light chain variable region and the light chain constant region of the PD-L1 antibody or antigen-binding fragment thereof.
43. The bispecific antibody or antigen-binding fragment thereof according to any one of claims 29-42, comprising a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain comprises, from N-terminus to C-terminus, the heavy chain variable region of the PD-L1 antibody or antigen-binding fragment thereof, the heavy chain constant region of the PD-L1 antibody or antigen-binding fragment thereof, a linker, and the VHH that specifically binds to CD39, and the second polypeptide chain comprises the light chain variable region and light chain constant region of the PD-L1 antibody or antigen-binding fragment thereof.
44. The bispecific antibody or antigen-binding fragment thereof according to any one of claims 29-42, comprising a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain comprises, from N-terminus to C-terminus, the VHH that specifically binds to CD39, a linker, the heavy chain variable region of the PD-L1 antibody or antigen-binding fragment thereof, and the heavy chain constant region of the PD-L1 antibody or antigen-binding fragment thereof, and the second polypeptide chain comprises the light chain variable region and light chain constant region of the PD-L1 antibody or antigen-binding fragment thereof.
45. A polypeptide comprising the antibody or antigen-binding fragment thereof of any one of claims 1-25, or the bispecific antibody or antigen-binding fragment thereof of any one of claims 26-44.
46. An isolated nucleic acid molecule or molecules encoding the antibody or antigen-binding fragment thereof of any one of claims 1-25, or the bispecific antibody or antigen-binding fragment thereof of any one of claims 26-44.
47. The nucleic acid molecule according to claim 46, further comprising a nucleic acid molecule encoding other proteins.
48. The nucleic acid molecule of claim 47, wherein the other protein comprises a chimeric antigen receptor (CAR).
49. A vector comprising the nucleic acid molecule of any one of claims 46-48.
50. The vector according to claim 49, wherein the nucleic acid molecule encoding the other protein and the nucleic acid molecule encoding the antibody or antigen-binding fragment thereof are located in the same vector.
51. The vector according to claim 49, wherein the nucleic acid molecule encoding the other protein and the nucleic acid molecule encoding the antibody or antigen-binding fragment thereof are located in different vectors.
52. A cell comprising the nucleic acid molecule of any one of claims 46-48, or the vector of any one of claims 49-51.
53. The cell of claim 52, comprising an immune cell.
54. The cell of claim 53, wherein the immune cells comprise T cells, NK cells, and / or macrophages.
55. The cell according to any one of claims 5-54, further comprising and / or expressing other proteins.
56. The cell of claim 55, wherein the other protein comprises a chimeric antigen receptor (CAR).
57. A pharmaceutical combination comprising the following components: (1) the antibody or antigen-binding fragment thereof according to any one of claims 1 to 25, or the bispecific antibody or antigen-binding fragment thereof according to any one of claims 26 to 44; (2) Cells.
58. The pharmaceutical combination of claim 57, wherein the cells comprise modified cells or unmodified cells.
59. A drug combination according to any one of claims 57-58, wherein the modified cells contain and / or express CAR.
60. The pharmaceutical combination of any one of claims 57-59, wherein the cells comprise immune cells.
61. The pharmaceutical combination according to any one of claims 57-60, wherein the cells comprise T cells, NK cells, and / or macrophages.
62. A method for preparing the antibody or antigen-binding fragment thereof of any one of claims 1-25, or the bispecific antibody or antigen-binding fragment thereof of any one of claims 26-44, comprising culturing the cell of any one of claims 52-56 under conditions where the antibody or antigen-binding fragment thereof of any one of claims 1-25, or the bispecific antibody or antigen-binding fragment thereof of any one of claims 26-44 is expressed.
63. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of any one of claims 1-25, the bispecific antibody or antigen-binding fragment thereof of any one of claims 26-44, the nucleic acid molecule of any one of claims 46-48, the vector of any one of claims 49-51, the cell of any one of claims 52-56, and / or the pharmaceutical combination of any one of claims 57-61, and optionally a pharmaceutically acceptable carrier.
64. Use of the antibody or antigen-binding fragment thereof of any one of claims 1-25, the bispecific antibody or antigen-binding fragment thereof of any one of claims 26-44, the nucleic acid molecule of any one of claims 46-48, the vector of any one of claims 49-51, the cell of any one of claims 52-56, the drug combination of any one of claims 57-61, and / or the pharmaceutical composition of claim 63 in the preparation of a medicament for preventing and / or treating a disease and / or condition.
65. The method of claim 64, wherein the disease and / or condition comprises a tumor.
66. The use according to claim 65, wherein the tumor comprises a solid tumor and / or a hematological tumor.
67. The use according to any one of claims 65-66, wherein the tumor comprises a tumor affected by CD39 activity.
68. A method for preventing and / or treating a disease and / or condition, comprising administering to a subject in need thereof an antibody or antigen-binding fragment thereof according to any one of claims 1-25, a bispecific antibody or antigen-binding fragment thereof according to any one of claims 26-44, a nucleic acid molecule according to any one of claims 46-48, a vector according to any one of claims 49-51, a cell according to any one of claims 52-56, a pharmaceutical combination according to any one of claims 57-61, and / or a pharmaceutical composition according to claim 63.
69. The method of claim 68, wherein the disease and / or condition comprises a tumor.
70. The method of claim 69, wherein the tumor comprises a solid tumor and / or a hematological tumor.
71. The method of any one of claims 69-70, wherein the tumor comprises a tumor affected by CD39 activity.
Citation Information
Patent Citations
Novel anti-CD39 antibodies
CN112714768A
Single-domain antibodies and variants thereof against tigit
CN111699198A
Anti-PD-L1 nanometer antibody
CN112409483A
Anti-PD-L1 antibodies and uses thereof
CN113087799A
CD3 humanized antibody and application thereof
CN116648462A
